Summary: AbbVie’s Q3 earnings will be announced on October 27th. This blue chip pharma offers
Summary: The US FDA has already approved two directly interchangeable biosimilars to ABBV’s Humira, namely
Summary: AbbVie is a leading pharmaceutical company with a strong history and a diverse portfolio
Summary: Dividend Kings are the most battle-tested dividend payers on Wall Street, with AbbVie being
Summary: AbbVie is expected to report a decline in EPS and revenue for Q3 2023,
Summary: Since its spin-off from Abbott Labs, AbbVie has delivered outstanding performance, surpassing both its
Summary: AbbVie has strong growth potential in various therapeutic and aesthetic markets, driven by novel
Summary: Currently, the S&P 500 and many sectors are outperforming the healthcare sector, presenting an
Summary: AbbVie has outperformed the S&P 500 since my previous update in early July, urging
Summary: AbbVie has shown resilience and strength despite the patent loss of its best-selling drug,